NuProbe

Executive Summary

NuProbe is a genomics and molecular diagnostics company headquartered in Houston, Texas, specializing in ultrasensitive and highly multiplexed assays for detecting low-frequency DNA variants. Its proprietary technologies, Blocker Displacement Amplification (BDA) and Quantitative Amplicon Sequencing (QASeq), enable detection of mutations, gene fusions, and copy number variations down to 0.01% variant allele frequency on both NGS and PCR platforms. The company focuses on accelerating precision oncology by providing research laboratories and biopharma partners with improved biomarker detection capabilities. Founded in 2016, NuProbe operates in the diagnostic space, leveraging its innovative methods to address critical challenges in liquid biopsy and early cancer detection. NuProbe's technology holds significant potential to enhance the sensitivity and specificity of molecular profiling, which could translate into earlier cancer diagnosis and better treatment monitoring. While the company is private and has not disclosed funding or revenue details, its novel assay platforms could attract partnerships with pharmaceutical companies seeking companion diagnostics or clinical trial enrichment tools. The growing demand for liquid biopsy solutions and precision medicine supports a favorable market environment. Key upcoming catalysts include potential commercial launches, clinical validation studies, and strategic collaborations, though timelines and success probabilities remain uncertain due to limited public information.

Upcoming Catalysts (preview)

• TBDLaunch of First Commercial NGS-Based Liquid Biopsy Assay50% success
• TBDStrategic Partnership with Top-Tier Pharmaceutical Company40% success
• TBDPublication of Key Clinical Validation Data60% success